Search

Your search keyword '"Domselaar, M."' showing total 185 results
Start Over Author "Domselaar, M."
185 results on '"Domselaar, M."'

1. DOP80 Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO Registry

Author

Chaparro, M, primary, García Donday, M, additional, Núñez Ortiz, A, additional, Calviño Suarez, C, additional, Rubio Iturria, S, additional, Sánchez Azofra, M, additional, Calvo Moya, M, additional, Pérez-Martínez, I, additional, Fernández-Clotet, A, additional, Alfambra, E, additional, Marín Pedrosa, S, additional, Diz-Lois Palomares, M T, additional, Hernandez, V, additional, Ruiz-Cerulla, A, additional, Casanova, M J, additional, Rivero, M, additional, Huguet, J M, additional, Vicente Lidón, R, additional, Árias García, L, additional, Guerra, I, additional, Hervías Cruz, D, additional, Gutiérrez Casbas, A, additional, Bejarano, A, additional, Camargo Camero, R, additional, Rodríguez-Lago, I, additional, Aguas, M, additional, De Jorge Turrión, M Á, additional, Masedo Gonzalez, Á, additional, López Serrano, P, additional, Valldosera Gomis, G, additional, Ceballos, D, additional, Bujanda, L, additional, Molina Arriero, G, additional, Vega Villaamil, P, additional, Van Domselaar, M, additional, Boscá Watts, M M, additional, Lucendo, A J, additional, Zúñiga de Mora-Figueroa, B, additional, Busquets, D, additional, and Gisbert, J P, additional

Published
2024
Full Text
View/download PDF

2. DOP08 A novel multiomic approach to unravel the mechanisms of action of biologics and tofacitinib in Inflammatory Bowel Disease

Author

Baldan-Martin, M, primary, Azkargorta, M, additional, Aransay, A M, additional, Gil-Redondo, R, additional, Moreno-Indias, I, additional, Iloro, I, additional, Soleto, I, additional, Orejudo, M, additional, Ramírez, C, additional, Lucendo, A J, additional, Rodríguez Gutiérrez, C, additional, Gutiérrez, A, additional, Martín Arranz, E, additional, Bujanda, L, additional, Rodríguez-Lago, I, additional, Riestra, S, additional, Iglesias-Flores, E, additional, Bermejo, F, additional, Van Domselaar, M, additional, García, M J, additional, Fernández Salazar, L, additional, De Prado, Á, additional, Calvet, X, additional, Torrealba, L, additional, Bastón Rey, I, additional, Pallarés, H, additional, Ber, Y, additional, Carnerero, E L, additional, Casanova, M J, additional, Millet, Ó, additional, Elortza, F, additional, Mato, J M, additional, Tinahones, F J, additional, Chaparro, M, additional, and Gisbert, J P, additional

Published
2024
Full Text
View/download PDF

3. P033 Unrevealing new potential key mechanisms implicated in inflammatory bowel disease by multiomic approach

Author

Baldan-Martin, M, primary, Azkargorta, M, additional, Aransay, A M, additional, Gil-Redondo, R, additional, Moreno-Indias, I, additional, Iloro, I, additional, Soleto, I, additional, Orejudo, M, additional, Ramírez, C, additional, Lucendo, A J, additional, Rodríguez Gutiérrez, C, additional, Gutiérrez, A, additional, Martín Arranz, E, additional, Bujanda, L, additional, Rodríguez-Lago, I, additional, Riestra, S, additional, Iglesias-Flores, E, additional, Bermejo, F, additional, Van Domselaar, M, additional, García, M J, additional, Fernández Salazar, L, additional, Barrio Andrés, J, additional, Calvet, X, additional, Torrealba, L, additional, Bastón Rey, I, additional, Pallarés, H, additional, Ber, Y, additional, Carnerero, E L, additional, Casanova, M J, additional, Casals, F, additional, Mendoza, J, additional, Moreno Monteagudo, J A, additional, Millet, Ó, additional, Elortza, F, additional, Mato, J M, additional, Tinahones, F J, additional, Chaparro, M, additional, and Gisbert, J P, additional

Published
2024
Full Text
View/download PDF

4. DOP22 Predictive biomarkers of therapeutic response in Inflammatory Bowel Disease: a step towards personalized medicine

Author

Baldan-Martin, M, primary, Azkargorta, M, additional, Aransay, A M, additional, Gil-Redondo, R, additional, Moreno-Indias, I, additional, Iloro, I, additional, Soleto, I, additional, Orejudo, M, additional, Ramírez, C, additional, Lucendo, A J, additional, Rodríguez Gutiérrez, C, additional, Gutiérrez, A, additional, Martín Arranz, E, additional, Bujanda, L, additional, Rodríguez-Lago, I, additional, Riestra, S, additional, Iglesias-Flores, E, additional, Bermejo, F, additional, Van Domselaar, M, additional, García, M J, additional, Fernández-Salazar, L, additional, García-Alonso, J F, additional, Calvet, X, additional, Torrealba, L, additional, Bastón Rey, I, additional, Pallarés, H, additional, Ber, Y, additional, Carnerero, E L, additional, Casanova, M J, additional, Millet, Ó, additional, Elortza, F, additional, Mato, J M, additional, Tinahones, F J, additional, Chaparro, M, additional, and Gisbert, J P, additional

Published
2024
Full Text
View/download PDF

5. P541 Diagnosis, management, and evolution of acute pancreatitis secondary to thiopurines in patients with Inflammatory Bowel Disease: an ENEIDA registry study

Author

Guerra Marina, I, primary, Barros, F, additional, Mesonero, F, additional, de Francisco, R, additional, Cañete, F, additional, Benítez, J M, additional, Sicilia, B, additional, Martín Arranz, M D, additional, de Castro, L, additional, Carbajo, A Y, additional, Gutiérrez, A, additional, Calvo, M, additional, Casanova, M J, additional, González-Muñoza, C, additional, Miguel, M, additional, Alfambra, E, additional, Rivero, M, additional, Lucendo, A J, additional, Tardillo, C A, additional, Almela, P, additional, Bujanda, L, additional, Van Domselaar, M, additional, Ramos, L, additional, Fernández Sánchez, M, additional, Hinojosa, E, additional, Verdejo, C, additional, Gimenez, A, additional, Piqueras, M, additional, Rodríguez-Lago, I, additional, Manceñido, N, additional, Pérez Calle, J L, additional, Moreno, M D P, additional, Delgado, P G, additional, Antolín, B, additional, Ramírez de la Piscina, P, additional, Bermejo, F, additional, Carracedo, Á, additional, Domènech, E, additional, and Gisbert, J P, additional

Published
2023
Full Text
View/download PDF

6. P905 Predictive pharmacogenetic risk of pancreatitis in Inflammatory Bowel Disease patients treated with thiopurines: a case-control study from the ENEIDA registry

Author

Guerra Marina, I, primary, Barros, F, additional, Chaparro, M, additional, Benítez, J M, additional, Martín Arranz, M D, additional, de Francisco, R, additional, Piqueras, M, additional, de Castro, L, additional, Carbajo, A Y, additional, Bermejo, F, additional, Mínguez, M, additional, Gutiérrez, A, additional, Mesonero, F, additional, Cañete, F, additional, González-Muñoza, C, additional, Calvo, M, additional, Sicilia, B, additional, Alfambra, E, additional, Tardillo, C A, additional, Rivero, M, additional, Lucendo, A J, additional, Bujanda, L, additional, Van Domselaar, M, additional, Almela, P, additional, Ramos, L, additional, Fernández Sánchez, M, additional, Hinojosa, E, additional, Verdejo, C, additional, Gimenez, A, additional, Rodríguez-Lago, I, additional, Manceñido, N, additional, Pérez Calle, J L, additional, Moreno, M D P, additional, Delgado-Guillena, P G, additional, Antolín, B, additional, Ramírez de la Piscina, P, additional, Casanova, M J, additional, Carracedo, Á, additional, Domènech, E, additional, and Gisbert, J P, additional

Published
2023
Full Text
View/download PDF

7. OP37 Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)

Author

Chaparro, M, primary, García Donday, M, additional, Riestra, S, additional, Lucendo, A J, additional, Benítez, J M, additional, Navarro-Llavat, M, additional, Barrio, J, additional, Morales-Alvarado, V J, additional, Rivero, M, additional, Busquets, D, additional, Leo Carnerero, E, additional, Merino Ochoa, O, additional, Nantes Castillejo, O, additional, Navarro, P, additional, Van Domselaar, M, additional, Gutiérrez Casbas, A, additional, Alonso-Abreu, I, additional, Mejuto, R, additional, Fernández Salazar, L, additional, Iborra, M, additional, Martín-Arranz, M D, additional, Pineda, J R, additional, Sampedro, M J, additional, Serra Nilsson, K, additional, Bouhmidi Assakali, A, additional, Batista, L, additional, Muñoz Villafranca, C, additional, Rodríguez-Lago, I, additional, Ceballos Santos, D S, additional, Guerra, I, additional, Mañosa, M, additional, Marín Jimenez, I, additional, Vera Mendoza, I, additional, Barreiro-de Acosta, M, additional, Domènech, E, additional, Esteve, M, additional, García-Sánchez, V, additional, Nos, P, additional, Panés, J, additional, and Gisbert, J P, additional

Published
2023
Full Text
View/download PDF

8. OP034 The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry

Author

Calafat, M, Mañosa, M, Cañete, F, Panés, J, García Sánchez, V, Calvo, M, Rodríguez-Moranta, F, Taxonera, C, Nos, P, López Sanromán, A, Martín Arranz, M D, Mínguez, M, Gisbert, J P, García-López, S, de Francisco, R, Gomollón, F, Calvet, X, Garcia-Planella, E, Rivero, M, Martínez-Cadilla, J, Argüelles, F, Arias García, L, Cimavilla, M, Zabana, Y, Márquez, L, Gutiérrez, A, Alcaín, G, Martínez Montiel, P, Lázaro, J, Busquets, D, García Sepulcre, M F, Verdejo, C, Bermejo, F, Mora, M, Monfort, D, Romero, P, Velayos, B, Rodríguez, C, Rodríguez, A, Merino, O, Rodríguez-Pescador, A, Bujanda, L, Ber, Y, Vela, M, Roncero, O, Huguet, J M, García-Bosch, O, Barreiro-de-Acosta, M, Madrigal, R E, Ramos, L, Van Domselaar, M, Almela, P, Llaó, J, Lucendo, A J, Muñoz Vilafranca, C, Abad, À, Charro, M, Legido, J, Riera, J, Khorrami, S, Sesé, E, Trapero, A M, and Domènech, E

Published
2018
Full Text
View/download PDF

9. P327 Evolution after a “de-intensification” strategy with anti-TNF therapy in patients with inflammatory bowel disease in clinical remission: multicenter study

Author

Benítez, J.M., Barreiro-de Acosta, M., Chaparro, M., Vázquez, J.M., Iglesias-Flores, E., Tosca, J., García-Planella, E., García-Lpez, S., Taxonera, C., Muñoz-Villafranca, M., Pajares, R., Barrio, J., Arias, L., Nantes, O., Fernández-Salazar, L., Hervías, D., Martín-Arranz, M., Mesonero, F., Moraleja-Yudejo, I., Pineda, J., Argüelles-Arias, F., Huguet, J., Hernández-Martínez, A., Pérez-Calle, J., Leo, E., Merino, O., Van Domselaar, M., Gutiérrez, A., Lorente, R., Castro, M., Algaba, A., Castro, E., Robles-Alonso, V., Ceballos, D., Gmez-García, R., Domínguez, J., Fernández, E., Vega-Lpez, A., Trapero, A., Talavera, A., Royo, V., Gisbert, J.P., and García-Sánchez, V.

Published
2017
Full Text
View/download PDF

10. DOP063 Serial tuberculin skin test improves the detection of latent tuberculosis infection in inflammatory bowel disease patients

Author

Taxonera, C., Ponferrada, A., Bermejo, F., Gisbert, J.P., Riestra, S., Saro, C., Cabriada, J.L., Barreiro-de Acosta, M., Barrio, J., Flores, E., Ferrer, I., Hernandez, A., Van Domselaar, M., Olivares, D., Alba, C., Fernández-Salazar, L., Merino, O., Botella, B., Ceballos, D., Moral, I., Peñate, M., and Algaba, A.

Published
2017
Full Text
View/download PDF

11. DOP016 Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of inflammatory bowel diseases: results from the multicenter European TEDDY study

Author

Chaparro, M., Verreth, A., Lobaton, T., Gravito-Soares, E., Julsgaard, M., Savarino, E., Magro, F., Avni Biron, I., Lpez-Serrano, P., Casanova, M., Gompertz, M., Vitor, S., Arroyo, M., Pugliese, D., Zabana, Y., Vicente, R., Aguas, M., Bar-Gil Shitrit, A., Gutierrez, A., Doherty, G., Fernández-Salazar, L., Martinez Cadilla, J., Huguet, J., OʼToole, A., Stasi, E., Manceñido Marcos, N., Villoria, A., Karmiris, K., Rahier, J., Rodriguez, C., Diz-Lois Palomares, M., Fiorino, G., Benítez, J., Principi, M., Naftali, T., Taxonera, C., Mantzaris, G., Sebkova, L., Iade, B., Lissner, D., Ferrer Bradley, I., Lpez-San Román, A., Marín-Jiménez, I., Merino, O., Sierra, M., Van Domselaar, M., Caprioli, F., Guerra, I., Peixe, P., Piqueras, M., Rodríguez-Lago, I., Ber, Y., Van Hoeve, K., Torres, P., Gravito-Soares, E., Rudbeck-Thomsen, D., Bartolo, O., Peixoto, A., Martín, G., Pérez, J., Garre, A., Donday, M.G., Martín de Carpi, J., and Gisbert, J.P.

Published
2017
Full Text
View/download PDF

13. Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease

Author

Casanova, MJ, Chaparro, M, Nantes, O, Varela, P, Vela-Gonzalez, M, Montserrat, R, Sierra, OG, Riestra, S, Barreiro-de Acosta, M, Martin-Rodriguez, MM, Gargallo-Puyuelo, CJ, Reygosa, C, Munoz, R, de la Filia-Molina, IG, Nunez-Ortiz, A, Kolle, L, Calafat, M, Huguet, JM, Iglesias-Flores, E, Martinez-Perez, TJ, Bosch, O, Duque-Alcorta, JM, Frago-Larramona, S, Sanchez-Azofra, M, Van Domselaar, M, Gonzalez-Cosano, VM, Bujanda, L, Rubio, S, Mancebo, A, Castro, B, Garcia-Lopez, S, de Francisco, R, Nieto, L, Laredo, V, Gutierrez, A, Mesonero, F, Leo-Carnerero, E, Canete, F, Ruiz, L, and Gisbert, JP

Published
2022

14. Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?

Author

Iglesias, RF, Silva, MSP, Marin, S, Casanova, MJ, Manosa, M, Gonzalez-Munoza, C, de Francisco, R, Caballol, B, Arias, L, Piqueras, M, Zabana, Y, Rivero, M, Calvet, X, Mesonero, F, Trastoy, PV, Nistal, RB, Perosanz, RG, Vega, P, Vivo, MG, Iborra, M, Marquez, LJ, Madero, L, Rodriguez-Lago, I, Gonzalez, MR, Vera, I, Diaz, AP, Vela, M, Torrealba, L, Van Domselaar, M, Iglesias, E, Gisbert, JP, Calafat, M, Garcia-Planella, E, Perez-Martinez, I, Ricart, E, Sicilia, B, Mena, R, Nieto, L, Domenech, E, and Acosta, MBD

Published
2022

15. Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU

Author

Barreiro-de Acosta, M, Riestra, S, Calafat, M, Soto, MP, Calvo, M, Rodriguez, ES, Caballol, B, Vela, M, Rivero, M, Munoz, F, de Castro, L, Calvet, X, Garcia-Alonso, FJ, Fornals, AU, Ferreiro-Iglesias, R, Gonzalez-Munoza, C, Chaparro, M, Bujanda, L, Sicilia, B, Alfambra, E, Rodriguez, A, Fernandez, RP, Rodriguez, C, Almela, P, Arguelles, F, Busquets, D, Tamarit-Sebastian, S, Castro, CR, Jimenez, L, Marin-Jimenez, I, Alcaide, N, Fernandez-Salgado, E, Iglesias, A, Ponferrada, A, Pajares, R, Roncero, O, Morales-Alvarado, VJ, Ispizua-Madariaga, N, Sainz, E, Merino, O, Marquez-Mosquera, L, Garcia-Sepulcre, M, Elorza, A, Estrecha, S, Suris, G, Van Domselaar, M, Brotons, A, de Francisco, R, Canete, F, Iglesias, E, Vera, MI, Mesonero, F, Lorente, R, Zabana, Y, Cabriada, JL, Domenech, E, Rodriguez-Lago, I, and Registry, ESGFTE

Subjects
surgery, Crohn's disease, enterocutaneous fistula, fistula
Abstract

Background and aims Crohn's disease [CD] can develop penetrating complications at any time during the disease course. Enterocutaneous fistulae [ECF] are disease-related complications with an important impact on quality of life. Our aim was to describe the outcomes of this complication, including its medical and/or surgical management and their temporal trends. The primary endpoint was fistula closure, defined as the absence of drainage, with no new abscess or surgery, over the preceding 6 months. Methods Clinical information from all adult patients with CD and at least one ECF-excluding perianal fistulae-were identified from the prospectively-maintained ENEIDA registry. All additional information regarding treatment for this complication was retrospectively reviewed. Results A total of 301 ECF in 286 patients [January 1970-September 2020] were analysed out of 30 088 records. These lesions were mostly located in the ileum [67%] and they had a median of one external opening [range 1-10]. After a median follow-up of 146 months (interquartile range [IQR], 69-233), 69% of patients underwent surgery. Fistula closure was achieved in 84%, mostly after surgery, and fistula recurrence was uncommon [13%]. Spontaneous and low-output fistulae were associated with higher closure rates (hazard ratio [HR] 1.51, 95% confidence interval [CI] 1.17-1.93, p = 0.001, and HR 1.49, 95% CI 1.07-2.06, p = 0.03, respectively); this was obtained more frequently with medical therapy since biologics have been available. Conclusions ECF complicating CD are rare but entail a high burden of medical and surgical resources. Closure rates are high, usually after surgery, and fistula recurrence is uncommon. A significant proportion of patients receiving medical therapy can achieve fistula closure.

Published
2022

16. P519 Analysis of the effectiveness and safety of switching from originator to biosimilar adalimumab in patients with Inflammatory Bowel Disease

Author

Casanova, M J, primary, Chaparro, M, additional, Nantes, Ó, additional, Varela, P, additional, Vela-González, M, additional, Montserrat, R, additional, Sierra, O G, additional, Riestra, S, additional, Barreiro-de Acosta, M, additional, Martín-Rodríguez, M M, additional, Gargallo-Puyuelo, C J, additional, Reygosa, C, additional, Muñoz, R, additional, García de la Filia-Molina, I, additional, Núñez-Ortiz, A, additional, Kolle, L, additional, Calafat, M, additional, Huguet, J M, additional, Iglesias-Flores, E, additional, Martínez-Pérez, T J, additional, Bosch, O, additional, Duque-Alcorta, J M, additional, Frago-Larramona, S, additional, Sánchez-Azofra, M, additional, Van Domselaar, M, additional, González-Cosano, V M, additional, Bujanda, L, additional, Rubio, S, additional, Mancebo, A, additional, Castro, B, additional, García-López, S, additional, de Francisco, R, additional, Nieto, L, additional, Laredo, V, additional, Gutiérrez, A, additional, Mesonero, F, additional, Leo-Carnerero, E, additional, Cañete, F, additional, Ruiz, L, additional, and Gisbert, J P, additional

Published
2022
Full Text
View/download PDF

17. P290 Therapeutic requirements in patients with Ulcerative Proctitis. Is it necessary immunosuppressive therapy in these patients?

Author

Ferreiro Iglesias, R, primary, Porto Silva, M S, additional, Marín, S, additional, Casanova, M J, additional, Mañosa, M, additional, González-Muñoza, C, additional, de Francisco, R, additional, Caballol, B, additional, Arias, L, additional, Piqueras, M, additional, Zabana, Y, additional, Rivero, M, additional, Calvet, X, additional, Mesonero, F, additional, Varela Trastoy, P, additional, Busta Nistal, R, additional, Gomez Perosanz, R, additional, Vega, P, additional, Gonzalez Vivo, M, additional, Iborra, M, additional, Jimenez Marquez, L, additional, Madero, L, additional, Rodríguez-Lago, I, additional, Rodriguez Gonzalez, M, additional, Vera, I, additional, Ponferrada Diaz, A, additional, Vela, M, additional, Torrealba, L, additional, Van Domselaar, M, additional, Iglesias, E, additional, Gisbert, J P, additional, Calafat, M, additional, García-Planella, E, additional, Perez-Martinez, I, additional, Ricart, E, additional, Sicilia, B, additional, Mena, R, additional, Nieto, L, additional, Domenech, E, additional, and Barreiro-de Acosta, M, additional

Published
2022
Full Text
View/download PDF

18. Inflammatory bowel disease in immigrants to Spain: results of the EIIMIGRA study from GETECCU (ENEIDA registry)

Author

Casbas A, Zapater P, Ricart E, Gonzalez-Vivo M, Gordillo J, Olivares D, Vera-Mendoza I, Manosa M, Gisbert J, Aguas M, Sanchez-Rodriguez E, Bosca M, Laredo V, Camps B, Marin-Jimenez I, Zabana Y, Martin-Arranz M, Munoz R, Navarro-Llavat M, Sierra E, Madero L, Vela M, Perez-Calle J, Sainz E, Calvet X, Sicilia B, Morales V, Bermejo F, Fernandez-Salazar L, Van Domselaar M, De Castro L, Rodriguez C, Munoz-Villafranca C, Lorente R, Rivero M, Iglesias E, Herreros B, Barreiro-de-Acosta M, Domenech E, Frances R, and EIIMIGRA

Published
2021

19. Inflammatory bowel disease in immigrants to Spain: results of the EIIMIGRA study from GETECCU (ENEIDA registry)

Author

Gutierrez Casbas, A., Zapater, P., Ricart, E., Gonzalez-Vivo, M., Gordillo, J., Olivares, D., Vera-Mendoza, I., Manosa, M., Gisbert, J. P., Aguas, M., Sanchez-Rodriguez, E., Bosca, M., Laredo, V., Camps, B., Marin-Jimenez, I., Zabana, Y., Martin-Arranz, M. D., Munoz, R., Navarro-Llavat, M., Sierra, E., Madero, L., Vela, M., Perez-Calle, J., Sainz, E., Calvet, X., Sicilia, B., Morales, V., Bermejo, F., Luis Fernández-Salazar, Domselaar, M., Castro, L., Rodriguez, C., Munoz-Villafranca, C., Lorente, R., Rivero, M., Iglesias, E., Herreros, B., Barreiro-De-Acosta, M., Domenech, E., and Frances, R.

Published
2021

20. P630 Inflammatory bowel disease in immigrants to Spain: results of the EIIMIGRA study from GETECCU (ENEIDA registry)

Author

Gutiérrez Casbas, A, primary, Zapater, P, additional, Ricart, E, additional, González-Vivó, M, additional, Gordillo, J, additional, Olivares, D, additional, Vera-Mendoza, I, additional, Mañosa, M, additional, Gisbert, J P, additional, Aguas, M, additional, Sánchez-Rodríguez, E, additional, Boscá, M, additional, Laredo, V, additional, Camps, B, additional, Marín-Jíménez, I, additional, Zabana, Y, additional, Martín-Arranz, M D, additional, Muñoz, R, additional, Navarro-Llavat, M, additional, Sierra, E, additional, Madero, L, additional, Vela, M, additional, Pérez-Calle, J, additional, Sainz, E, additional, Calvet, X, additional, Sicilia, B, additional, Morales, V, additional, Bermejo, F, additional, Fernández-Salazar, L, additional, Van Domselaar, M, additional, De Castro, L, additional, Rodríguez, C, additional, Muñoz-Villafranca, C, additional, Lorente, R, additional, Rivero, M, additional, Iglesias, E, additional, Herreros, B, additional, Barreiro-de-Acosta, M, additional, Domènech, E, additional, and Francés, R, additional

Published
2021
Full Text
View/download PDF

22. Long-term evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (IBD): A multicentre study

Author

Casanova M, Chaparro M, Nantes O, Benitez J, Rojas-Feria M, Castro-Poceiro J, Huguet J, Martin-Cardona A, Aicart M, Tosca J, Martin-Rodriguez M, Gonzalez-Munoza C, Manosa M, Leo-Carnerero E, Lamuela L, Perez-Martinez I, Bujanda L, Hinojosa J, Pajares R, Arguelles-Arias F, Perez-Calle J, Rodriguez-Gonzalez G, Guardiola J, Barreiro-de Acosta M, Bermejo F, Barrio J, Beltran B, Gomollon F, Lorente R, Gutierrez A, Dominguez-Cajal M, Duenas C, Ponferrada-Diaz A, Van Domselaar M, Ramirez-de la Piscina P, Ramos L, Almela P, Navarro-Llavat M, Botella B, Gisbert J, and EVODIS

Published
2020

23. Real-world long-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA registry

Author

Colomino, M, Beltran, B, Fernandez-Clotet, A, Flores, E, Navarro, P, Rivero, M, Gutierrez, A, Sierra-Ausin, M, Mesonero, F, Ferreiro-Iglesias, R, Hinojosa, J, Calvet, X, Sicilia, B, Gonzalez-Munoza, C, Antolin, B, Vivo, M, Carbajo, A, Garcia, S, Martin-Cardona, A, Marin, G, Martin-Arranz, M, De Francisco, R, Canete, F, Carlos, T, Gomollon, F, Lorente, R, Rodriguez-Lago, I, Fores-Bosch, A, Bernardos, E, Ramos, L, Delgado, P, Hernandez, A, Van Domselaar, M, Hervas, D, Domenech, E, and Nos, P

Published
2020

25. P462 Efficacy of ustekinumab for the prevention of postoperative recurrence in crohn’s disease. Data from clinical practice from the eneida registry

Author

Mañosa Ciria, M, primary, Fernandez-Clotet, A, additional, Hernández-Camba, A, additional, Muñoz Pérez, R, additional, Iborra, M, additional, Sierra, M, additional, Márquez, L, additional, Delgado-Guillena, P, additional, Busquets, D, additional, Van Domselaar, M, additional, Girona, E, additional, Sánchez-Rodríguez, E, additional, Martín-Arranz, M D, additional, Lorente, R, additional, Casas-Deza, D, additional, Boscá, M, additional, Cañete, F, additional, Calafat, M, additional, and Domènech, E, additional

Published
2020
Full Text
View/download PDF

26. P501 Thiopurine withdrawal in patients with Crohn’s disease: the SURESTE study

Author

Sánchez Rodríguez, E, primary, Sánchez Aldehuelo, R, additional, Guardiola, J, additional, Gutiérrez Casbas, A, additional, Domènech, E, additional, Bermejo, F, additional, Van-Domselaar, M, additional, Mesonero Gismero, F, additional, Suris, G, additional, Muñoz Perez, R, additional, Mañosa, M, additional, Jiménez Márquez, L, additional, Algaba García, A, additional, and López sanroman, A, additional

Published
2020
Full Text
View/download PDF

27. P386 Long-term evolution after anti-TNF discontinuation in patients with inflammatory bowel disease (IBD): A multicentre study

Author

Casanova, M J, primary, Chaparro, M, additional, Nantes, O, additional, Benítez, J M, additional, Rojas-Feria, M, additional, Castro-Poceiro, J, additional, Huguet, J M, additional, Martín-Cardona, A, additional, Aicart, M, additional, Tosca, J, additional, Martín-Rodríguez, M D M, additional, González-Muñoza, C, additional, Mañosa, M, additional, Leo-Carnerero, E, additional, Lamuela, L, additional, Pérez-Martínez, I, additional, Bujanda, L, additional, Hinojosa, J, additional, Pajares, R, additional, Argüelles-Arias, F, additional, Pérez-Calle, J L, additional, Rodríguez-González, G E, additional, Guardiola, J, additional, Barreiro-de Acosta, M, additional, Bermejo, F, additional, Barrio, J, additional, Beltrán, B, additional, Gomollón, F, additional, Lorente, R, additional, Gutierrez, A, additional, Domínguez-Cajal, M, additional, Dueñas, C, additional, Ponferrada-Díaz, A, additional, Van Domselaar, M, additional, Ramírez-de la Piscina, P, additional, Ramos, L, additional, Almela, P, additional, Navarro-Llavat, M, additional, Botella, B, additional, and Gisbert, J P, additional

Published
2020
Full Text
View/download PDF

28. P537 Real-world long-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA registry

Author

Iborra Colomino, M I, primary, Beltrán, B, additional, Fernández-Clotet, A, additional, Iglesias Flores, E, additional, Navarro, P, additional, Rivero, M, additional, Gutiérrez, A, additional, Sierra-Ausin, M, additional, Mesonero, F, additional, Ferreiro-Iglesias, R, additional, Hinojosa, J, additional, Calvet, X, additional, Sicilia, B, additional, González-Muñoza, C, additional, Antolín, B, additional, González Vivo, M, additional, Carbajo, A Y, additional, García, S, additional, Martín-Cardona, A, additional, Surís Marín, G, additional, Martín-Arranz, M D, additional, De Francisco, R, additional, Cañete, F, additional, Carlos, T, additional, Gomollón, F, additional, Lorente, R, additional, Rodríguez-Lago, I, additional, Forés-Bosch, A, additional, Bernardos, E, additional, Ramos, L, additional, Delgado, P, additional, Hernández, A, additional, Van Domselaar, M, additional, Hervás, D, additional, Domènech, E, additional, and Nos, P, additional

Published
2020
Full Text
View/download PDF

31. Clinical characteristics, associated malignancies and management of primary sclerosing cholangitis in inflammatory bowel disease patients: A multicenter retrospective cohort study

Author

Guerra I, Bujanda L, Castro J, Merino O, Tosca J, Camps B, Gutiérrez A, Gordillo Ábalos J, de Castro L, Iborra M, Carbajo AY, Taxonera C, Rodríguez-Lago I, Mesonero F, de Francisco R, Gómez-Gómez GJ, Chaparro M, Tardillo CA, Rivero M, Algaba A, Martín Arranz E, Cañete F, Vicente R, Sicilia B, Antolín B, Prieto V, Márquez L, Benítez JM, Camo P, Piqueras M, Gargallo CJ, Hinojosa E, Huguet JM, Pérez Calle JL, Van Domselaar M, Rodriguez C, Calvet X, Muñoz-Villafranca C, García-Sepulcre MF, Munoz-Garrido P, Fernández-Clotet A, Gómez Irwin L, Hernández S, Guardiola J, Sempere L, González Muñoza C, Hernández V, Beltrán B, Barrio J, Alba C, Moraleja I, López-Sanromán A, Riestra S, Martínez Montiel P, Garre A, Arranz L, García MJ, Martín Arranz MD, Corsino P, Arias L, Fernández-Salazar L, Fernández-Pordomingo A, Andreu M, Iglesias E, Ber Y, Mena R, Arroyo Villarino MT, Mora M, Ruiz L, López-Serrano P, Blazquez I, Villoria A, Fernández M, Bermejo F, Banales JM, Domènech E, and Gisbert JP

Subjects
endocrine system diseases, digestive, oral, and skin physiology, inflammatory bowel disease, malignancy, primary sclerosing cholangitis, digestive system, digestive system diseases
Abstract

Primary sclerosing cholangitis (PSC) is usually associated with inflammatory bowel disease (IBD). An increased risk of malignancies, mainly colorectal cancer (CRC) and cholangiocarcinoma (CCA), has been reported in PSC-IBD patients. Our aim was to determine the clinical characteristics and management of PSC in IBD patients, and the factors associated with malignancies.

Published
2019

32. Increased risk of thiopurine-related adverse events in elderly patients with IBD

Author

Calafat, M, Maosa, M, Caete, F, Ricart, E, Iglesias, E, Calvo, M, Rodrguez-Moranta, F, Taxonera, C, Nos, P, Mesonero, F, Martn-Arranz, MD, Mnguez, M, Gisbert, JP, Garca-Lpez, S, de Francisco, R, Gomolln, F, Calvet, X, Garcia-Planella, E, Rivero, M, Martnez-Cadilla, J, Argelles, F, Arias, L, Cimavilla, M, Zabana, Y, Domnech, E, Abad, A, Alcain, G, Almela, P, Barreiro-de-Acosta, M, Ber, Y, Bermejo, F, Bujanda, L, Busquets, D, Charro, M, Garca-Bosch, O, Garca-Sepulcre, MF, Gutirrez, A, Khorrami, S, Lzaro, J, Legido, J, Lia, J, Lucendo, AJ, Madrigal, RE, Mrquez, L, Martnez-Montiel, P, Merino, O, Monfort, D, Mora, M, Muoz-Villafranca, C, Ramos, L, Riera, J, Prez, AR, Gutirrez, CR, Rodrguez-Pescador, A, Romero, P, Roncero, O, Ses, E, Trapero, AM, Van Domselaar, M, Vela, M, Velayos, B, Verdejo, C, and Huguet, JM

Abstract

Background Thiopurines are the most widely used immunosuppressants in IBD although drug-related adverse events (AE) occur in 20%-30% of cases. Aim To evaluate the safety of thiopurines in elderly IBD patients Methods Cohort study including all adult patients in the ENEIDA registry who received thiopurines. Patients were grouped in terms of age at the beginning of thiopurine treatment, specifically in those who started thiopurines over 60 years or between 18 and 50 years of age. Thiopurine-related AEs registered in the ENEIDA database were compared. Results Out of 48 752 patients, 1888 thiopurines when over 60 years of age and 15 477 under 50 years of age. Median treatment duration was significantly shorter for those who started thiopurines >60 years (13 [IQR 2-55] vs 32 [IQR 5-82] months; P < .001). Patients starting >60 years had higher rates of all types of myelotoxicity, digestive intolerance and hepatotoxicity. Thiopurines were discontinued due to AEs (excluding malignancies and infections) in more patients starting >60 years (67.2% vs 63.1%; P < .001). Elderly age and female sex were independent risk factors for most AEs. Conclusion In elderly IBD patients, thiopurines are associated with an increased risk of non-infectious, non-neoplastic, AEs.

Published
2019

33. Clinical features, therapeutic requirements, and evolution of patients with Crohn's disease and upper digestive tract involvement (CROHNEX study)

Author

Sainz Arnau, E., Zabana, Y., Miguel, I., Fernandez Clotet, A., Casanova, M. J., Martin, M. D., Pico, M. D., Alfambra, E., Rodriguez, I., Munoz, F., Dominguez, M., Iglesias, E., Busquets, D., Gutierrez, A., Canete, F., Nunez, L., Taxonera, C., Beltran, B., Camps, B., Calvet, X., Navarro, P., Calafat, M., Ferreiro-Iglesias, R., Gonzalez-Munoza, C., Sicilia, B., Rodriguez, C., Carbajo, A. Y., Domselaar, M., Vicente, R., Piqueras, M., Munoz, M. C., Abad, A., Algaba, A., Martinez, P., Vela, M. I., Antolin, B., Huguet, J. M., Luis Bujanda, Lorente, R. H., Almela, P., Garcia, M. J., Ramirez La Piscina, P., Pajares, R., Perez-Martinez, I., Lucendo, A. J., Merino, O., Legido, J., Vera, I., Morales, V. J., and Esteve, M.

Published
2019

34. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

Author

Chaparro, M, Garre, A, Ricart, E, Iglesias-Flores, E, Taxonera, C, Manosa, M, Mendoza, IV, Minguez, M, Arguelles, F, Parga, LD, Arroyo, M, Lopez-Sanroman, A, Tirado, MR, Guardiola, J, Arranz, MDM, Beltran, B, Barrio, J, Riestra, S, Garcia-Planella, E, Calvet, X, Alcain, G, Sicilia, B, Garcia, S, Esteve, M, Marquez, L, Salazar, LIF, Casbas, AG, Piqueras, M, Bermejo, F, Calle, JLP, Hinojosa, J, Perez, AR, Aldeguer, X, Sepulcre, MFG, Bujanda, L, Montiel, PM, Poyatos, RL, Gutierrez, CR, Merino, O, Cabriada, JL, Roncero, O, Cara, PR, Navarro-Llavat, M, Ber, Y, Madrigal, RE, Van Domselaar, M, Barreiro-de Acosta, M, Llao, J, Ramos, L, Riera, J, Villarin, AJL, Gonzalez, ER, Malaves, JMH, Villafranca, CM, Almela, P, Charro, M, de la Piscina, PR, Sese, E, Lacruz, AA, Khorrami, S, Alvarado, VJM, Gil, JL, Martinez, AMT, Villaroya, RP, Acevedo, J, Herola, AG, Villalba, LH, Munoz, E, Duran, MTN, Menacho, M, Lopez, VMN, Retamero, MD, Bernardo, D, Muriel, A, Domenech, E, Gisbert, JP, and ENEIDA Study Grp

Abstract

Background Cohort studies comparing the characteristics of childhood-onset and adulthood-onset inflammatory bowel disease (IBD) in the biologics era are scarce. Aim To compare disease characteristics, the use of immunomodulators and biologic agents and the need for surgery between childhood- and adulthood-onset IBD. Methods Inflammatory bowel disease patients from the ENEIDA registry diagnosed between 2007 and 2017 were included. The childhood-onset cohort comprised patients diagnosed at 16 years. The cumulative incidences of immunosuppressive therapy, biologic therapy and surgery were estimated using Kaplan-Meier curves, compared by the log-rank test. Cox regression analysis was performed to identify potential predictive factors of treatment with immunosuppressants, biologic agents or surgery. Results The adulthood-onset cohort comprised 21 200 patients out of 20 354 (96%) and the childhood-onset cohort 846 (4%). Median follow-up was 54 months in the childhood-onset cohort and 38 months in the adulthood-onset cohort (P < 0.01). Proportions of Crohn's disease, ileocolonic involvement and inflammatory behaviour at diagnosis were higher in the childhood-onset cohort. In the multivariate analysis, after adjusting for sex, type of IBD, extraintestinal manifestations, family history and smoking habit, childhood-onset IBD was associated with higher risk of immunomodulator use (hazard ratio [HR] = 1.2, 95% confidence interval [95% CI] = 1.1-1.2) and higher probability of receiving biologic treatment (HR = 1.2, 95% CI = 1.1-1.3). However, childhood-onset IBD was not associated with higher risk of surgery (HR = 0.9, 95% CI = 0.8-1.2). Conclusions Childhood-onset IBD has differential characteristics and higher risk of treatment with immunomodulators and biologic agents, compared with adulthood-onset IBD. Nevertheless, paediatric IBD is not associated with higher risk of surgery.

Published
2019

35. Effectiveness and Safety of the Switch from Remicade (R) to CT-P13 in Patients with Inflammatory Bowel Disease

Author

Chaparro, M, Garre, A, Veloz, MFG, Moron, JMV, De Castro, ML, Leo, E, Rodriguez, E, Carbajo, AY, Riestra, S, Jimenez, I, Calvet, X, Bujanda, L, Rivero, M, Gomollon, F, Benitez, JM, Bermejo, F, Alcaide, N, Gutierrez, A, Manosa, M, Iborra, M, Lorente, R, Rojas-Feria, M, Barreiro-de Acosta, M, Kolle, L, Van Domselaar, M, Amo, V, Arguelles, F, Ramirez, E, Morell, A, Bernardo, D, and Gisbert, JP

Subjects
Crohn's disease, Remicade (R), +CT-P13%22">sup > CT-P13, Inflammatory bowel disease, switch, ulcerative colitis
Abstract

Background and Aims: To evaluate the clinical outcomes in patients with IBD after switching from Remicade (R) to CT-P13 in comparison with patients who maintain Remicade (R). Methods: Patients under Remicade (R) who were in clinical remission with standard dosage at study entry were included. The 'switch cohort' [SC] comprised patients who made the switch from Remicade (R) to CT-P13, and the 'non-switch' cohort [NC] patients remained under Remicade (R). Results: A total of 476 patients were included: 199 [42%] in the SC and 277 [58%] in the NC. The median follow-up was 18 months in the SC and 23 months in the NC [p < 0.01]. Twenty-four out of 277 patients relapsed in the NC; the incidence of relapse was 5% per patient-year. The cumulative incidence of relapse was 2% at 6 months and 10% at 24 months in this group. Thirty-eight out of 199 patients relapsed in the SC; the incidence rate of relapse was 14% per patient-year. The cumulative incidence of relapse was 5% at 6 months and 28% at 24 months. In the multivariate analysis, the switch to CT-P13 was associated with a higher risk of relapse (HR = 3.5, 95% confidence interval [CI] = 2-6). Thirteen percent of patients had adverse events in the NC, compared with 6% in the SC [p < 0.05]. Conclusions: Switching from Remicade (R) to CT-P13 might be associated with a higher risk of clinical relapse, although this fact was not supported in our study by an increase in objective markers of inflammation. The nocebo effect might have influenced this result. Switching from Remicade (R) to CT-P13 was safe.

Published
2019

36. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry

Author

Iborra, M, Beltran, B, Fernandez-Clotet, A, Gutierrez, A, Antolin, B, Huguet, J, De Francisco, R, Merino, O, Carpio, D, Garcia-Lopez, S, Mesonero, F, Navarro, P, Ferreiro-Iglesias, R, Carbajo, A, Rivero, M, Gisbert, J, Pinero-Perez, M, Monfort, D, Bujanda, L, Garcia-Sepulcre, M, Martin-Cardona, A, Canete, F, Taxonera, C, Domenech, E, Nos, P, Sierra-Ausin, M, Ferrer-Rosique, J, Martin-Arranz, M, Gonzalez-Munoza, C, Mancenido, N, Rodriguez-Lago, I, Benitez, J, Fores-Bosch, A, Navarro-Llavat, M, Calafat, M, Madrigal-Dominguez, R, Ramos, L, Arroyo, M, Busquets, D, Lorente, R, Sainz-Arnau, E, Hernandez-Camba, A, Morales-Alvarado, V, Paredes, J, Van Domselaar, M, Hervas, D, Canada-Martinez, A, Castro-Poceiro, J, Cameo-Lorenzo, J, Fernandez-Salazar, L, Riestra, S, Casas-Deza, D, Tosca, J, Barrio, J, Garcia, M, Chaparro, M, and GETECCU Grp Grp Espanol Trab

Abstract

Background There are limited data of ustekinumab administered according to the doses recommended in the UNITI studies. Aim To assess the real-world, short-term effectiveness of ustekinumab in refractory Crohn's disease (CD) Methods Multicentre study of CD patients starting ustekinumab after June 2017 at the recommend dose (260, 390 or 520 mg based on weight ~6 mg/kg IV week 0 and 90 mg subcutaneously week 8). Values for Harvey-Bradshaw Index (HBI), C-reactive protein (CRP) and faecal calprotectin (FC) were recorded at baseline and at weeks 8 and 14. Demographic and clinical data, previous treatments, AEs and hospitalisations were documented. Possible predictors of clinical remission were examined. Results Three hundred and five patients were analysed (>= 2 previous anti-TNF alpha therapies 64% and vedolizumab 29%). At baseline, 217 (72%) had an HBI >4 points. Of these, 101 (47%) and 126 (58%) achieved clinical remission at weeks 8 and 14, respectively. FC levels returned to normal (

Published
2019

37. Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry

Author

Calafat, M, Manosa, M, Panes, J, Nos, P, Iglesias, E, Vera, I, Lopez-Sanroman, A, Guardiola, J, Taxonera, C, Minguez, M, Martin, MD, de Castro, L, Riestra, S, Rivero, M, Garcia-Planella, E, Calvet, X, Garcia-Lopez, S, Andreu, M, Gomollon, F, Barrio, J, Esteve, M, Rodriguez, A, Gisbert, JP, Gutierrez, A, Hinojosa, J, Arguelles, F, Busquets, D, Bujanda, L, Lazaro, J, Sicilia, B, Merino, O, Martinez, P, Bermejo, F, Lorente, R, Barreiro-de-Acosta, M, Rodriguez, C, Fe, M, Piqueras, M, Romero, P, Rodriguez, E, Roncero, O, Llao, J, Alcain, G, Riera, J, Sierra, M, Salazar, LIF, Jair, V, Navarro, M, Montoro, MA, Munoz, C, Lucendo, AJ, Van Domselaar, M, Moraleja, I, Huguet, M, Ramos, L, Ramirez, P, Almeda, P, Pajares, R, Khorrami, S, Madrigal, RE, Sese, E, Trapero, AM, Legido, J, Abad, A, Canete, F, Cabre, E, and Domenech, E

Published
2019

38. Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease

Author

Instituto de Salud Carlos III, Chaparro‐Muñoz, Marinela, Garre, A., Guerra Veloz, M. F., Vázquez Morón, J. M., Castro, M. L. de, Leo Carnerero, Eduardo, Rodríguez, Estefanía, Carbajo, A. Y., Riestra, Sabino, Jiménez, I., Calvet, X., Bujanda, Luis, Rivero, M., Gomollón, F., Benítez, José María, Bermejo, F., Alcaide, N., Gutiérrez, A., Mañosa, Miriam, Iborra, M., Lorente, Rafael, Rojas-Feria, M., Barreiro-de Acosta, M., Kolle, L., Van Domselaar, M., Amo, V., Argüelles Arias, Federico, Ramírez, E., Morell, A., Bernardo, David, Gisbert, J. P., Instituto de Salud Carlos III, Chaparro‐Muñoz, Marinela, Garre, A., Guerra Veloz, M. F., Vázquez Morón, J. M., Castro, M. L. de, Leo Carnerero, Eduardo, Rodríguez, Estefanía, Carbajo, A. Y., Riestra, Sabino, Jiménez, I., Calvet, X., Bujanda, Luis, Rivero, M., Gomollón, F., Benítez, José María, Bermejo, F., Alcaide, N., Gutiérrez, A., Mañosa, Miriam, Iborra, M., Lorente, Rafael, Rojas-Feria, M., Barreiro-de Acosta, M., Kolle, L., Van Domselaar, M., Amo, V., Argüelles Arias, Federico, Ramírez, E., Morell, A., Bernardo, David, and Gisbert, J. P.

Abstract

[Background and Aims] To evaluate the clinical outcomes in patients with IBD after switching from Remicade® to CT-P13 in comparison with patients who maintain Remicade®., [Methods] Patients under Remicade® who were in clinical remission with standard dosage at study entry were included. The ‘switch cohort’ [SC] comprised patients who made the switch from Remicade® to CT-P13, and the ‘non-switch’ cohort [NC] patients remained under Remicade®., [Results] A total of 476 patients were included: 199 [42%] in the SC and 277 [58%] in the NC. The median follow-up was 18 months in the SC and 23 months in the NC [p < 0.01]. Twenty-four out of 277 patients relapsed in the NC; the incidence of relapse was 5% per patient-year. The cumulative incidence of relapse was 2% at 6 months and 10% at 24 months in this group. Thirty-eight out of 199 patients relapsed in the SC; the incidence rate of relapse was 14% per patient-year. The cumulative incidence of relapse was 5% at 6 months and 28% at 24 months. In the multivariate analysis, the switch to CT-P13 was associated with a higher risk of relapse (HR = 3.5, 95% confidence interval [CI] = 2–6). Thirteen percent of patients had adverse events in the NC, compared with 6% in the SC [p < 0.05]., [Conclusions] Switching from Remicade® to CT-P13 might be associated with a higher risk of clinical relapse, although this fact was not supported in our study by an increase in objective markers of inflammation. The nocebo effect might have influenced this result. Switching from Remicade® to CT-P13 was safe.

Published
2019

39. Long-Term Safety of In Utero Exposure to Anti-TNF alpha Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study

Author

Chaparro M, Verreth A, Lobaton T, Gravito-Soares E, Julsgaard M, Savarino E, Magro F, Avni Biron I, Lopez-Serrano P, Casanova MJ, Gompertz M, Vitor S, Arroyo M, Pugliese D, Zabana Y, Vicente R, Aguas M, Bar-Gil Shitrit A, Gutierrez A, Doherty GA, Fernandez-Salazar L, Martínez Cadilla J, Huguet JM, O'Toole A, Stasi E, Manceñido Marcos N, Villoria A, Karmiris K, Rahier JF, Rodriguez C, Diz-Lois Palomares M, Fiorino G, Benitez JM, Principi M, Naftali T, Taxonera C, Mantzaris G, Sebkova L, Iade B, Lissner D, Ferrer Bradley I, Lopez-San Roman A, Marin-Jimenez I, Merino O, Sierra M, Van Domselaar M, Caprioli F, Guerra I, Peixe P, Piqueras M, Rodriguez-Lago I, Ber Y, van Hoeve K, Torres P, Gravito-Soares M, Rudbeck-Resdal D, Bartolo O, Peixoto A, Martin G, Armuzzi A, Garre A, Donday MG, Martín-de-Carpi J, and Gisbert JP

Abstract

OBJECTIVES: The long-term safety of exposure to anti-tumor necrosis factor (anti-TNF alpha) drugs during pregnancy has received little attention. We aimed to compare the relative risk of severe infections in children of mothers with inflammatory bowel disease (IBD) who were exposed to anti-TNF alpha drugs in utero with that of children who were not exposed to the drugs. METHODS: Retrospective multicenter cohort study. Exposed cohort: children from mothers with IBD receiving anti-TNF alpha medication (with or without thiopurines) at any time during pregnancy or during the 3 months before conception. Non-exposed cohort: children from mothers with IBD not treated with anti-TNF alpha agents or thiopurines at any time during pregnancy or the 3 months before conception. The cumulative incidence of severe infections after birth was estimated using Kaplan-Meier curves, which were compared using the log-rank test. Cox-regression analysis was performed to identify potential predictive factors for severe infections in the offspring. RESULTS: The study population comprised 841 children, of whom 388 (46%) had been exposed to anti-TNF alpha agents. Median follow-up after delivery was 47 months in the exposed group and 68 months in the non-exposed group. Both univariate and multivariate analysis showed the incidence rate of severe infections to be similar in non-exposed and exposed children (1.6% vs. 2.8% per person-year, hazard ratio 1.2 (95% confidence interval 0.8-1.8)). In the multivariate analysis, preterm delivery was the only variable associated with a higher risk of severe infection (2.5% (1.5-4.3)). CONCLUSIONS: In utero exposure to anti-TNF alpha drugs does not seem to be associated with increased short-term or long-term risk of severe infections in children.

Published
2018

40. Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease

Author

Taxonera, C, Ponferrada, A, Riestra, S, Bermejo, F, Saro, C, Martin-Arranz, MD, Cabriada, JL, Barreiro-de Acosta, M, de Castro, ML, Lopez-Serrano, P, Barrio, J, Suarez, C, Iglesias, E, Arguelles-Arias, F, Ferrer, I, Marin-Jimenez, I, Hernandez-Camba, A, Bastida, G, Van Domselaar, M, Martinez-Montiel, P, Olivares, D, Rivero, M, Fernandez-Salazar, L, Nantes, O, Merino, O, Alba, C, Gisberty, JP, Martin-Rodriguez, MD, Botella, B, Carpio, D, Ceballos, D, Verdejo, C, Morales, I, Legido, J, Penate, M, Chaparro, M, Algaba, A, de Francisco, R, and CONVERT Study Grp GETECCU

Subjects
Crohn's disease, immunosuppressants, inflammatory bowel disease, latent tuberculosis infection, Tuberculosis, tuberculin skin test, anti-TNF, bacterial infections and mycoses, ulcerative colitis, corticosteroids
Abstract

Aim: To assess the likelihood of detecting latent tuberculosis infection [LTBI] by the positive conversion of a serial tuberculin skin test [TST] at 1 year in inflammatory bowel disease [IBD] patients with negative baseline two-step TST. Methods: In this multicentre prospective cohort study, we evaluated rate and predictors of conversion of TST at 1 year in patients with negative baseline TST. We also evaluated management of patients who had a positive TST at baseline or a conversion at 1 year. In all patients we assessed TB cases occurring during follow-up. Results: Of the 192 IBD patients receiving anti-tumour necrosis factor [TNF] and 220 IBD controls not receiving anti-TNF, 35 [8.5%, 95% CI 5.7-11.3] had positive conversion (median TST induration 13 mm, interquartile range [IQR] 9-16). Ten anti-TNF cohort patients [5.2%, 95% CI 2.5-9.5] versus 25 controls [11.4%, 95% CI 7.5-16.3] had TST conversion [p = 0.029]. In multivariate analysis, conversion was associated with smoking habit (odds ratio [OR] 2.19, 95% CI 1.08-3.97; p = 0.028). Anti-TNF-treated patients had a lower conversion rate [OR 0.41, 95% CI 0.20-0.83; p = 0.013]. The likelihood of conversion correlates with fewer immunosuppressive therapies between baseline TST and TST at 1 year [p = 0.042]. One case of active TB [isoniazid-resistant strain] occurred in a patient with positive baseline TST receiving anti-TNF [0.05 events/100 patient-years]. Conclusions: Serial TST at 1 year can detect LTBI in IBD patients receiving anti-TNF therapy with negative baseline TST. Serial TST seems to be advisable to reduce the risk of TB cases associated with inability to detect LTBI in pre-treatment screening.

Published
2018

41. Idiopathic acute pancreatitis in patients with inflammatory bowel disease: a multicentric cohort study

Author

García García de Paredes, A., primary, Rodríguez-Escaja, C., additional, Iborra, M., additional, Algaba, A., additional, Cameo, J.I., additional, de la Peña, L., additional, Gomollón, F., additional, Van Domselaar, M., additional, Busta, R., additional, Rodríguez de Santiago, E., additional, Castaño García, A., additional, del Val, A., additional, Bermejo, F., additional, Gutiérrez, A., additional, Guardiola, J., additional, Mesonero, F., additional, Riestra, S., additional, Nos, P., additional, Albillos, A., additional, and López-Sanromán, A., additional

Published
2019
Full Text
View/download PDF

42. Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease

Author

Chaparro, M, primary, Garre, A, additional, Guerra Veloz, M F, additional, Vázquez Morón, J M, additional, De Castro, M L, additional, Leo, E, additional, Rodriguez, E, additional, Carbajo, A Y, additional, Riestra, S, additional, Jiménez, I, additional, Calvet, X, additional, Bujanda, L, additional, Rivero, M, additional, Gomollón, F, additional, Benítez, J M, additional, Bermejo, F, additional, Alcaide, N, additional, Gutiérrez, A, additional, Mañosa, M, additional, Iborra, M, additional, Lorente, R, additional, Rojas-Feria, M, additional, Barreiro-de Acosta, M, additional, Kolle, L, additional, Van Domselaar, M, additional, Amo, V, additional, Argüelles, F, additional, Ramírez, E, additional, Morell, A, additional, Bernardo, D, additional, and Gisbert, J P, additional

Published
2019
Full Text
View/download PDF

43. P437 Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry

Author

Calafat, M, primary, Mañosa, M, additional, Panes, J, additional, Nos, P, additional, Iglesias, E, additional, Vera, I, additional, López-Sanromán, A, additional, Guardiola, J, additional, Taxonera, C, additional, Mínguez, M, additional, Martín, M D, additional, de Castro, L, additional, Riestra, S, additional, Rivero, M, additional, García-Planella, E, additional, Calvet, X, additional, García-López, S, additional, Andreu, M, additional, Gomollón, F, additional, Barrio, J, additional, Esteve, M, additional, Rodríguez, A, additional, Gisbert, J P, additional, Gutierrez, A, additional, Hinojosa, J, additional, Argüelles, F, additional, Busquets, D, additional, Bujanda, L, additional, Lázaro, J, additional, Sicilia, B, additional, Merino, O, additional, Martínez, P, additional, Bermejo, F, additional, Lorente, R, additional, Barreiro-de-Acosta, M, additional, Rodríguez, C, additional, Fe, M, additional, Piqueras, M, additional, Romero, P, additional, Rodríguez, E, additional, Roncero, Ó, additional, Llaó, J, additional, Alcaín, G, additional, Riera, J, additional, Sierra, M, additional, Fdez. Salazar, L I, additional, Jair, V, additional, Navarro, M, additional, Montoro, M A, additional, Muñoz, C, additional, Lucendo, A J, additional, Van Domselaar, M, additional, Moraleja, I, additional, Huguet, J M, additional, Ramos, L, additional, Ramírez, P, additional, Almeda, P, additional, Pajares, R, additional, Khorrami, S, additional, Madrigal, R E, additional, Sesé, E, additional, Trapero, A M, additional, Legido, J, additional, Abad, Á, additional, Cañete, F, additional, Cabré, E, additional, and Domènech, E, additional

Published
2019
Full Text
View/download PDF

44. P505 Real-world short-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA Registry

Author

Iborra, M, primary, Beltrán, B, additional, Fernández, A, additional, Gutiérrez, A, additional, Antolín, B, additional, Huguet, J M, additional, de Francisco, R, additional, Merino, O, additional, Carpio, D, additional, García López, S, additional, Mesonero, F, additional, Mínguez, M, additional, Ferreiro, R, additional, Carbajo, A Y, additional, Rivero, M, additional, Chaparro, M, additional, Piñero-Pérez, M C, additional, Monfort i Miquel, D, additional, Bujanda, L, additional, García-Sepulcre, M F, additional, Martín-Cardona, A, additional, Cañete, F, additional, Taxonera, C, additional, Sierra-Ausin, M, additional, Ferrer-Rosique, J Á, additional, Martín-Arranz, M D, additional, González-Muñosa, C, additional, Manceñido-Marcos, N, additional, Rodríguez-Lago, I, additional, Iglesias-Flores, E, additional, Forés-Bosch, A, additional, Navarro-Llavat, M, additional, Calafat, M, additional, Madrigal-Domínguez, R E, additional, Ramos, L, additional, Arroyo, M, additional, Busquets, D, additional, Lorente, R, additional, Saiz-Arnau, E, additional, Hernández-Camba, A, additional, Jair-Morales, V, additional, Paredes, C, additional, Van Domselaar, M, additional, Hervás, D, additional, Cañada-Martínez, A, additional, and Nos, P, additional

Published
2019
Full Text
View/download PDF

45. P443 Clinical features, therapeutic requirements, and evolution of patients with Crohn's disease and upper digestive tract involvement (CROHNEX study)

Author

Sainz Arnau, E, primary, Zabana, Y, additional, Miguel, I, additional, Fernández Clotet, A, additional, Casanova, M J, additional, Martín, M D, additional, Picó, M D, additional, Alfambra, E, additional, Rodriguez, I, additional, Muñoz, F, additional, Domínguez, M, additional, Iglesias, E, additional, Busquets, D, additional, Gutiérrez, A, additional, Cañete, F, additional, Nuñez, L, additional, Taxonera, C, additional, Beltrán, B, additional, Camps, B, additional, Calvet, X, additional, Navarro, P, additional, Calafat, M, additional, Ferreiro-Iglesias, R, additional, González-Muñoza, C, additional, Sicilia, B, additional, Rodríguez, C, additional, Carbajo, A Y, additional, van Domselaar, M, additional, Vicente, R, additional, Piqueras, M, additional, Muñoz, M C, additional, Abad, À, additional, Algaba, A, additional, Martínez, P, additional, Vela, M I, additional, Antolín, B, additional, Huguet, J M, additional, Bujanda, L, additional, Lorente, R H, additional, Almela, P, additional, García, M J, additional, Ramírez de la Piscina, P, additional, Pajares, R, additional, Pérez-Martínez, I, additional, Lucendo, A J, additional, Merino, O, additional, Legido, J, additional, Vera, I, additional, Morales, V J, additional, and Esteve, M, additional

Published
2019
Full Text
View/download PDF

46. P439 Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the ENEIDA registry

Author

Casanova, M J, primary, Chaparro, M, additional, Mínguez, M, additional, Ricart, E, additional, Taxonera, C, additional, García-López, S, additional, Guardiola, J, additional, López-San Román, A, additional, Iglesias, E, additional, Beltrán, B, additional, Sicilia, B, additional, Vera, M I, additional, Hinojosa, J, additional, Riestra, S, additional, Domènech, E, additional, Calvet, X, additional, Pérez-Calle, J L, additional, Martín-Arranz, M D, additional, Aldeguer, X, additional, Rivero, M, additional, Monfort, D, additional, Barrio, J, additional, Esteve, M, additional, Márquez, L, additional, Lorente, R, additional, García-Planella, E, additional, de Castro, L, additional, Bermejo, F, additional, Merino, O, additional, Rodríguez-Pérez, A, additional, Martínez-Montiel, P, additional, Van Domselaar, M, additional, Alcaín, G, additional, Domínguez-Cajal, M, additional, Muñoz, C, additional, Gomollón, F, additional, Fernández-Salazar, L, additional, García-Sepulcre, M F, additional, Rodríguez-Lago, I, additional, Gutiérrez, A, additional, Argüelles-Arias, F, additional, Rodriguez, C, additional, Rodríguez, G E, additional, Bujanda, L, additional, Llaó, J, additional, Varela, P, additional, Ramos, L, additional, Huguet, J M, additional, Almela, P, additional, Romero, P, additional, Navarro-Llavat, M, additional, Abad, Á, additional, Ramírez-de la Piscina, P, additional, Lucendo, A J, additional, Sesé, E, additional, Madrigal, R E, additional, Charro, M, additional, García-Herola, A, additional, Pajares, R, additional, Khorrami, S, additional, and Gisbert, J P, additional

Published
2019
Full Text
View/download PDF

47. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

Author

Chaparro, María, primary, Donday, María G., additional, Barreiro-de Acosta, Manuel, additional, Domènech, Eugeni, additional, Esteve, María, additional, García-Sánchez, Valle, additional, Nos, Pilar, additional, Panés, Julián, additional, Martínez, Concepción, additional, Gisbert, Javier P., additional, Abad, F., additional, Aguas Peris, M., additional, Agüero Tejado, E., additional, Alba, C., additional, Albert, M., additional, Alemán, H., additional, Algaba, A., additional, Alonso Abreu, I., additional, Amador, M.P., additional, Amat, M., additional, Angueira, T., additional, Arajol, C., additional, Arias-González, L., additional, Arrondo Velasco, A., additional, Baldán, M., additional, Bardán García, B., additional, Bargalló García, A., additional, Barreiro de Acosta, M., additional, Barrio Andrés, J., additional, Bastida Paz, G., additional, Bastón Rey, I., additional, Batista, L., additional, Bellver Martínez, M., additional, Beltrán Niclós, B., additional, Benítez, J.M., additional, Ber Nieto, Y., additional, Bermejo, F., additional, Bernardo, D., additional, Blázquez Gómez, I., additional, Bouhmidi Assakali, A., additional, Busquets Casals, D., additional, Cabriada Nuño, J.L., additional, Calvet Calvo, X., additional, Calvo Hernández, M.V., additional, Calvo, M., additional, Camps, B., additional, Carbajo, A.Y., additional, Cardona Peitx, G., additional, Caro-Patón, T., additional, Carrillo Palau, M., additional, Carrión Bolorino, S., additional, Casanova, M.J., additional, Casellas Valdé, J.A., additional, Castaño García, A., additional, Castro Senosiain, B., additional, Ceballos, D., additional, Cerrillo, E., additional, Chacón Martínez, S., additional, Consuelo Cañete Pizarro, F., additional, de Castro Parga, M.L., additional, de Miguel, M., additional, de Francisco García, R., additional, de la Cruz Ramírez, M.D., additional, del Hoyo Francisco, J., additional, Delgado Guillena, P., additional, Desongles Corrales, T., additional, Echarri Piudo, A., additional, Espino Paisan, E., additional, Espona Quer, M., additional, Fernández Pordomingo, A., additional, Fernández Forcelledo, J.L., additional, Fernández-Tomé, S., additional, Ferreiro Iglesias, R., additional, Ferrer Bradley, I., additional, Ferrer, A., additional, Figueroa, A., additional, Gallach Montero, M., additional, García Iglesias, P., additional, García García-Lezcún, C., additional, García Ramírez, L., additional, García García, M.J., additional, García-Bosh, O., additional, Garre, A., additional, Giménez Poderós, T., additional, Gómez Irwin, L., additional, Gómez Pastrana, B., additional, Gómez Delgado, E., additional, González Lama, Y., additional, Gracia García, Á., additional, Gracia García, B., additional, Guardiola, J., additional, Guerra, I., additional, Guerra, E., additional, Guillot, V., additional, Gustmancher Saiz, S., additional, Gutiérrez Casbas, A., additional, Hernández Ramírez, V., additional, Hernando Verdugo, M.M., additional, Hernández Muniesa, B., additional, Hernanz Chaves, R., additional, Herrera Justiniano, J.M., additional, Hinojosa del Val, J, additional, Ibáñez Feijoo, S, additional, Iborra Colomino, M, additional, Iglesias Flores, E, additional, Izquierdo García, E., additional, Sampedro González, M J, additional, Lucendo, A J., additional, Jiménez García, N, additional, Leo Carnerero, E., additional, Loizaga Díaz, I., additional, López de Torre Querejazu, A, additional, López Sánchez, P, additional, Luis Parras, J, additional, Maia Boscá, M, additional, Mañosa, M, additional, Marín Pedrosa, S, additional, Marín, A, additional, Marinero, Á, additional, Marín-Jiménez, I, additional, Márquez Mosquera, L, additional, Márquez Galán, JL, additional, Martín Arranz, E, additional, Martín Arranz, MD, additional, Martínez Cadilla, J, additional, Martínez Sesmero, JM, additional, Martínez Sánchez, B, additional, Matallana, V, additional, Mateos Hernández, MI, additional, McNicholl, AG, additional, Mejuto Fernández, R, additional, Melcarne, L, additional, Menchén, L, additional, Méndez-Castrillón Rodríguez, J, additional, Merino Ochoa, O, additional, Mínguez, M, additional, Molas Ferrer, G, additional, Montoro Huguet, M, additional, Montserrat Torres, A, additional, Mora, F, additional, Moraleja Yudego, I, additional, Morales Alvarado, VJ, additional, Morales Martínez, L, additional, Morell, A, additional, Motos García, C, additional, Muñoz Alonso, F, additional, Muñoz Villafranca, MC, additional, Muñoz, JE, additional, Mur, A, additional, Nantes, Ó, additional, Navarro, P, additional, Navarro- Llavat, M, additional, Nos Mateu, P, additional, Núñez Alonso, A, additional, Núñez Ortiz, A, additional, Olivares, D, additional, Ollero Pena, V, additional, Orobitg, J, additional, Ortega, L, additional, Ortiz de Zárate, J, additional, Pallarés Manrique, H, additional, Paradela Carreiro, A, additional, Peral Ballester, L, additional, Pereira Bueno, S, additional, Pérez Martínez, I, additional, Pineda Mariño, JR, additional, Piñero Pérez, C, additional, Planas Giner, A, additional, Plaza Santos, MR, additional, Ponferrada Díaz, Á, additional, Poza Cardón, J, additional, Prieto Vicente, V, additional, Puchades, L, additional, Ramos López, L, additional, Redondo, S, additional, Riestra Menéndez, S, additional, Rivero Tirado, M, additional, Rodríguez Lago, I, additional, Rodríguez Gutiérrez, C, additional, Rodríguez, E, additional, Romero Izquierdo, S, additional, Rubio Iturria, S, additional, Ruiz Antorán, MB, additional, Ruiz, A, additional, Salazar, LF, additional, Sánchez Ulayar, A, additional, Sánchez Gómez, E, additional, Sánchez, C, additional, Sangrador, C, additional, Serra, K, additional, Spicakova, K, additional, Suárez Ferrer, C, additional, Talavera Fabuel, A, additional, Taxonera, C, additional, Tordera, M, additional, Torrella Cortés, E, additional, Tosca, J, additional, Trigo Salado, C, additional, Uriarte Estefanía, F, additional, Van Domselaar, M, additional, Vázquez Morón, JM, additional, Ventura López, P, additional, Vera, M, additional, Vicuña Arregui, M, additional, Villoria Ferrer, A, additional, Virgós Aller, T, additional, and Yáñez Feria, D, additional

Published
2019
Full Text
View/download PDF

49. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

Author

Casanova MJ, Chaparro M, García-Sánchez V, Nantes O, Leo E, Rojas-Feria M, Jauregui-Amezaga A, García-López S, Huguet JM, Arguelles-Arias F, Aicart M, Marín-Jiménez I, Gómez-García M, Muñoz F, Esteve M, Bujanda L, Cortés X, Tosca J, Pineda JR, Mañosa M, Llaó J, Guardiola J, Pérez-Martínez I, Muñoz C, González-Lama Y, Hinojosa J, Vázquez JM, Martinez-Montiel MP, Rodríguez GE, Pajares R, García-Sepulcre MF, Hernández-Martínez A, Pérez-Calle JL, Beltrán B, Busquets D, Ramos L, Bermejo F, Barrio J, Barreiro-de Acosta M, Roncedo O, Calvet X, Hervías D, Gomollón F, Domínguez-Antonaya M, Alcaín G, Sicilia B, Dueñas C, Gutiérrez A, Lorente-Poyatos R, Domínguez M, Khorrami S, Taxonera C, Rodríguez-Pérez A, Ponferrada A, Van Domselaar M, Arias-Rivera ML, Merino O, Castro E, Marrero JM, Martín-Arranz M, Botella B, Fernández-Salazar L, Monfort D, Opio V, García-Herola A, Menacho M, Ramírez-de la Piscina P, Ceballos D, Almela P, Navarro-Llavat M, Robles-Alonso V, Vega-López AB, Moraleja I, Novella MT, Castaño-Milla C, Sánchez-Torres A, Benítez JM, Rodríguez C, Castro L, Garrido E, Domènech E, García-Planella E, and Gisbert JP

Subjects
Male, Constriction, Pathologic, Inflammatory bowel disease, Gastroenterology, Deprescriptions, 0302 clinical medicine, Crohn Disease, Recurrence, Risk Factors, Medicine, Young adult, Mesalamine, Aged, 80 and over, Incidence, Incidence (epidemiology), Remission Induction, Age Factors, Middle Aged, Antirheumatic Agents, 030220 oncology & carcinogenesis, Retreatment, Disease Progression, Female, 030211 gastroenterology & hepatology, Tumor necrosis factor alpha, Adult, medicine.medical_specialty, Adolescent, Drug-Related Side Effects and Adverse Reactions, Colon, Young Adult, 03 medical and health sciences, Ileum, Internal medicine, Humans, Immunologic Factors, Colitis, Aged, Proportional Hazards Models, Retrospective Studies, Hepatology, Tumor Necrosis Factor-alpha, business.industry, Proportional hazards model, Adalimumab, Retrospective cohort study, Protective Factors, Inflammatory Bowel Diseases, medicine.disease, Infliximab, Discontinuation, Methotrexate, Colitis, Ulcerative, business, Follow-Up Studies
Abstract

OBJECTIVES: The aims of this study were to assess the risk of relapse after discontinuation of anti-tumor necrosis factor (anti-TNF) drugs in patients with inflammatory bowel disease (IBD), to identify the factors associated with relapse, and to evaluate the overcome after retreatment with the same anti-TNF in those who relapsed. METHODS: This was a retrospective, observational, multicenter study. IBD patients who had been treated with anti-TNFs and in whom these drugs were discontinued after clinical remission was achieved were included. RESULTS: A total of 1,055 patients were included. The incidence rate of relapse was 19% and 17% per patient-year in Crohn's disease and ulcerative colitis patients, respectively. In both Crohn's disease and ulcerative colitis patients in deep remission, the incidence rate of relapse was 19% per patient-year. The treatment with adalimumab vs. infliximab (hazard ratio (HR)=1.29; 95% confi dence interval (CI)= 1.01-1.66), elective discontinuation of anti-TNFs (HR=1.90; 95% CI= 1.07-3.37) or discontinuation because of adverse events (HR= 2.33; 95% CI= 1.27-2.02) vs. a top-down strategy, colonic localization (HR= 1.51; 95% CI= 1.13-2.02) vs. ileal, and stricturing behavior (HR= 1.5; 95% CI= 1.09-2.05) vs. inflammatory were associated with a higher risk of relapse in Crohn's disease patients, whereas treatment with immunomodulators after discontinuation (HR= 0.67; 95% CI= 0.51-0.87) and age (HR= 0.98; 95% CI= 0.97-0.99) were protective factors. None of the factors were predictive in ulcerative colitis patients. Retreatment of relapse with the same anti-TNF was effective (80% responded) and safe. CONCLUSIONS: The incidence rate of infl ammatory bowel disease relapse after anti-TNF discontinuation is relevant. Some predictive factors of relapse after anti-TNF withdrawal have been identifi ed. Retreatment with the same anti-TNF drug was effective and safe.

Published
2017

50. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients (vol 52, pg 788, 2017)

Author

Iborra M, Gisbert J, Bosca-Watts M, Lopez-Garcia A, Garcia-Sanchez V, Lopez-Sanroman A, Hinojosa E, Marquez L, Garcia-Lopez S, Chaparro M, Aceituno M, Calafat M, Guardiola J, Belloc B, Ber Y, Bujanda L, Beltran B, Rodriguez-Gutierrez C, Barrio J, Cabriada J, Rivero M, Camargo R, van Domselaar M, Villoria A, Schuterman H, Hervas D, Nos P, and Spanish Working Grp on Crohn's Dis

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results